Diferencia entre revisiones de «Test serológicos Covid19»
Sin resumen de edición |
Sin resumen de edición |
||
Línea 6: | Línea 6: | ||
{| class="wikitable" |
{| class="wikitable" |
||
|+ |
|+ |
||
!Test/Manufacturador |
!<small>Test/Manufacturador</small> |
||
!Ac medido |
!<small>Ac medido</small> |
||
!n pos |
!<small>n pos</small> |
||
!<small>n</small> |
|||
!n |
|||
controles |
<small>controles</small> |
||
!<small>S</small> |
|||
!S |
|||
!<small>E</small> |
|||
!E |
|||
!Referencias |
!<small>Referencias</small> |
||
Comentarios usos |
<small>Comentarios usos</small> |
||
|- |
|- |
||
|STANDARD Q COVID-19 |
|<small>STANDARD Q COVID-19</small> |
||
⚫ | |||
⚫ | |||
⚫ | |||
SD BIOSENSOR (tipo test pack) |
SD BIOSENSOR (tipo test pack) |
||
<br /> |
<br /></small> |
||
|IgM/IgG |
|<small>IgM/IgG</small> |
||
|<small>33</small> |
|||
|33 |
|||
|<small>30</small> |
|||
|30 |
|||
|IgM 63,3% |
|<small>IgM 63,3%</small> |
||
IgG 81.8% |
<small>IgG 81.8%</small> |
||
IgM + IgG 81.8% |
<small>IgM + IgG 81.8%</small> |
||
IgM dp D8: 77.8% |
<small>IgM dp D8: 77.8%</small> |
||
IgM dp D10: 81.8% |
<small>IgM dp D10: 81.8%</small> |
||
IgG dp D8: 92.6% |
<small>IgG dp D8: 92.6%</small> |
||
IgG dp D10: 95.8% |
<small>IgG dp D10: 95.8%</small> |
||
|100% |
|<small>100%</small> |
||
96.6% |
<small>96.6%</small> |
||
96.6% |
<small>96.6%</small> |
||
100% |
<small>100%</small> |
||
100% |
<small>100%</small> |
||
96.6% |
<small>96.6%</small> |
||
96.6% |
<small>96.6%</small> |
||
|http://sdbiosensor.com/xe/product/7662. |
|<small>http://sdbiosensor.com/xe/product/7662.</small> |
||
<small><br /> |
|||
Muestras de sangre, suero, plasma, 10 ul 10 min<br /> |
Muestras de sangre, suero, plasma, 10 ul 10 min<br /></small> |
||
|- |
|- |
||
|Lateral flow immunoassay (tipo test pack) |
|<small>Lateral flow immunoassay (tipo test pack)</small> |
||
|IgM + IgG <br /> |
|<small>IgM + IgG <br /></small> |
||
|397 |
|<small>397</small> |
||
|128 |
|<small>128</small> |
||
|88.7% |
|<small>88.7%</small> |
||
352 + |
<small>352 +</small> |
||
|90.63% |
|<small>90.63%</small> |
||
12 c+ |
<small>12 c+</small> |
||
|Zhengtu Li et al. J Med Virol 2020 27Feb. doi: [https://doi.org/10.1101/2020.02.27.20028787 https://doi.org/10.1002/jmv.25727]. |
|<small>Zhengtu Li et al. J Med Virol 2020 27Feb. doi: [https://doi.org/10.1101/2020.02.27.20028787 https://doi.org/10.1002/jmv.25727].</small> |
||
Rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. |
<small>Rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories.</small> |
||
Muestras consistencia suero y gota de sangre<br /> |
<small>Muestras consistencia suero y gota de sangre<br /></small> |
||
|- |
|- |
||
|ELISA Gold inmunocromatográfico colloidal (GICA) |
|<small>ELISA Gold inmunocromatográfico colloidal (GICA)</small> |
||
<small><br /> |
|||
⚫ | |||
⚫ | |||
⚫ | |||
|<small>IgM e IgG</small> |
|||
|<small>63 ELISA</small> |
|||
<small>91 GICA<br /></small> |
|||
⚫ | |||
|<small>35</small> |
|||
|IgM e IgG |
|||
| |
|<small>ELISA:</small> |
||
<small>IgM 44.4%</small> |
|||
⚫ | |||
|35 |
|||
|ELISA: |
|||
<small>IgG 82.5%</small> |
|||
IgM 44.4% |
|||
⚫ | |||
IgG 82.5% |
|||
<small>GICA:</small> |
|||
⚫ | |||
<small>IgM 57.1%</small> |
|||
GICA: |
|||
<small>IgG 81.3%</small> |
|||
IgM 57.1% |
|||
⚫ | |||
IgG 81.3% |
|||
⚫ | |||
| |
| |
||
<small>100%</small> |
|||
100% |
<small>100%</small> |
||
100% |
<small>100%</small> |
||
<small><br /></small> |
|||
100% |
|||
<small>100%</small> |
|||
<small>100%</small> |
|||
100% |
<small>100%</small> |
||
⚫ | |||
100% |
|||
100% |
|||
⚫ | |||
<small><br /> |
|||
PCR + en 59% (varios en recuperación, no indican días de evolución) |
PCR + en 59% (varios en recuperación, no indican días de evolución) |
||
<br /> |
<br /></small> |
||
|- |
|- |
||
|Quimoluminiscencia (CHL) |
|<small>Quimoluminiscencia (CHL)</small> |
||
ELISA (doble sandwich) |
<small>ELISA (doble sandwich)</small> |
||
GICA (point of care) |
<small>GICA (point of care)</small> |
||
|Ac totales, IgM |
|<small>Ac totales, IgM</small> |
||
| |
| |
||
| |
| |
||
|CHL: |
|<small>CHL:</small> |
||
Ac totales 86.9% |
<small>Ac totales 86.9%</small> |
||
IgM 74.3% |
<small>IgM 74.3%</small> |
||
ELISA: |
<small>ELISA:</small> |
||
Ac totales 94.8% |
<small>Ac totales 94.8%</small> |
||
IgM 86.9% |
<small>IgM 86.9%</small> |
||
GICA: |
<small>GICA:</small> |
||
Ac totales 96.2% |
<small>Ac totales 96.2%</small> |
||
IgM 87.9% |
<small>IgM 87.9% |
||
<br /> |
<br /></small> |
||
|95.2-100% |
|<small>95.2-100%</small> |
||
|Xia et al. [https://doi.org/10.1101/2020.02.27.20028787 doi:https://doi.org/10.20944/preprints202003.0184.v1]. |
|<small>Xia et al. [https://doi.org/10.1101/2020.02.27.20028787 doi:https://doi.org/10.20944/preprints202003.0184.v1].</small> |
||
(No peer reviewed) |
<small>(No peer reviewed)</small> |
||
Testear casos oligo o asintomáticos para indicar cuarentena |
<small>Testear casos oligo o asintomáticos para indicar cuarentena |
||
<br /> |
<br /></small> |
||
|- |
|- |
||
|Inmunoensayo |
|<small>Inmunoensayo</small> |
||
quimoluminiscente |
<small>quimoluminiscente</small> |
||
|IgM IgG |
|<small>IgM IgG</small> |
||
|<small>3</small> |
|||
|3 |
|||
|225 |
|<small>225</small> |
||
|Se + 7-12 d después |
|<small>Se + 7-12 d después</small> |
||
del inicio de síntomas |
<small>del inicio de síntomas</small> |
||
|98-100% |
|<small>98-100%</small> |
||
|Zhang et al. MedXriv pre print https://doi.org/10.1101/2020.03.04.20030916. |
|<small>Zhang et al. MedXriv pre print https://doi.org/10.1101/2020.03.04.20030916.</small> |
||
<br /> |
<small><br /></small> |
||
|- |
|- |
||
|Inmunocromatográfico |
|<small>Inmunocromatográfico</small> |
||
|IgM IgG |
|<small>IgM IgG</small> |
||
|139 m |
|<small>139 m</small> |
||
105 p |
<small>105 p</small> |
||
76 p+ |
<small>76 p+</small> |
||
8 - > + |
<small>8 - > +</small> |
||
<br /> |
<small><br /></small> |
||
|37 m |
|<small>37 m</small> |
||
39 p |
<small>39 p</small> |
||
|IgM |
|<small>IgM</small> |
||
1-7 d 11.1% |
<small>1-7 d 11.1%</small> |
||
8-14 d 78.6% |
<small>8-14 d 78.6%</small> |
||
>15 d 74.2% |
<small>>15 d 74.2%</small> |
||
<small>IgG</small> |
|||
IgG |
|||
1-7 d 3.6% |
<small>1-7 d 3.6%</small> |
||
8-14 d 57.1% |
<small>8-14 d 57.1%</small> |
||
>15 d 96.8% |
<small>>15 d 96.8%</small> |
||
IgM IgG |
<small>IgM IgG</small> |
||
8-14: 92.9% |
<small>8-14: 92.9%</small> |
||
| |
| |
||
|Pan et al. MedRxiv preprint<nowiki/>https://doi.org/10.1101/2020.03.13.20035428. |
|<small>Pan et al. MedRxiv preprint</small><nowiki/><small>https://doi.org/10.1101/2020.03.13.20035428.</small> |
||
<small><br /> |
|||
36% IgM + y 59% IgG + en casos PCR neg |
36% IgM + y 59% IgG + en casos PCR neg</small> |
||
|- |
|- |
||
|CLIA (quemoluminiscente) |
|<small>CLIA (quemoluminiscente)</small> |
||
GICA (Gold inmunocromatográfico |
<small>GICA (Gold inmunocromatográfico</small> |
||
coloidal) |
<small>coloidal)</small> |
||
ELISA |
|||
<small>ELISA</small> |
|||
<small><br /> |
|||
Beier Bioengineering Company (Beijing) contra S y N |
Beier Bioengineering Company (Beijing) contra S y N |
||
<br /> |
<br /></small> |
||
|IgM IgG |
|<small>IgM IgG</small> |
||
|37 m |
|<small>37 m</small> |
||
22 p+<br /> |
<small>22 p+<br /></small> |
||
|<small>NA</small> |
|||
|NA |
|||
|IgM (al menos uno +) |
|<small>IgM (al menos uno +)</small> |
||
1-7 d 6/10 |
<small>1-7 d 6/10</small> |
||
8-14 d 7/13 |
<small>8-14 d 7/13</small> |
||
>15 d 11/14 |
<small>>15 d 11/14</small> |
||
IgG (al menos uno +) |
<small>IgG (al menos uno +)</small> |
||
1-7 d 5/10 |
<small>1-7 d 5/10</small> |
||
8-14 d 10/13 |
<small>8-14 d 10/13</small> |
||
>15 d 14/14 |
<small>>15 d 14/14 |
||
<br /> |
<br /></small> |
||
| |
| |
||
|Hui-Xia Gao et al. Chinese Medical Journal 2020. DOI: https://doi.org/10.1097/CM9.0000000000000820 |
|<small>Hui-Xia Gao et al. Chinese Medical Journal 2020. DOI: https://doi.org/10.1097/CM9.0000000000000820</small> |
||
<small><br /> |
|||
GICA mejor para IgM |
GICA mejor para IgM</small> |
||
ELISA mejor para IgG |
<small>ELISA mejor para IgG</small> |
||
|- |
|- |
||
|ELISA contra N |
|<small>ELISA contra N</small> |
||
|IgA, IgG e IgM |
|<small>IgA, IgG e IgM</small> |
||
|208 m |
|<small>208 m</small> |
||
82 p+ |
<small>82 p+</small> |
||
58 p- |
<small>58 p-</small> |
||
|285 |
|<small>285</small> |
||
|IgM |
|<small>IgM</small> |
||
1-7 d 35/41 85.4% |
<small>1-7 d 35/41 85.4%</small> |
||
Mediana + |
<small>Mediana +</small> |
||
IgM e IgA 7 d (3-6) |
<small>IgM e IgA 7 d (3-6)</small> |
||
IgG 14 d (10-18) |
<small>IgG 14 d (10-18)</small> |
||
IgM casos confirmados 75.6% |
<small>IgM casos confirmados 75.6%</small> |
||
IgM casos probables 93.2% |
<small>IgM casos probables 93.2%</small> |
||
Dp D5 + IgM>S que PCR |
<small>Dp D5 + IgM>S que PCR</small> |
||
S PCR: |
<small>S PCR:</small> |
||
1-3 d >90% |
<small>1-3 d >90%</small> |
||
D6 <80% (57.1-95.7) |
<small>D6 <80% (57.1-95.7)</small> |
||
D14 <50% (23.7-59.5) |
<small>D14 <50% (23.7-59.5)</small> |
||
| |
| |
||
|Guo et al. Respuesta inmune precoz. https://doi.org/10.1093/cid/ciaa310/5810754 |
|<small>Guo et al. Respuesta inmune precoz. https://doi.org/10.1093/cid/ciaa310/5810754</small> |
||
S PCR (1 test): 51.9% |
<small>S PCR (1 test): 51.9%</small> |
||
S IgM + PCR: 98.6% |
<small>S IgM + PCR: 98.6%</small> |
||
Reactividad cruzada con SARS-Covid, no con otros coronavirus |
<small>Reactividad cruzada con SARS-Covid, no con otros coronavirus</small> |
||
Proponen uso en: |
<small>Proponen uso en:</small> |
||
Casos sospechosos PCR - |
<small>Casos sospechosos PCR -</small> |
||
Estudios de seroprevalencia y conocer tasa de asintomáticos |
<small>Estudios de seroprevalencia y conocer tasa de asintomáticos</small> |
||
Conocer estado inmune de personal de salud |
<small>Conocer estado inmune de personal de salud</small> |
||
Detectar casos subclínicos |
<small>Detectar casos subclínicos</small> |
||
|- |
|- |
||
|ELISA Contra S |
|<small>ELISA Contra S</small> |
||
|IgM, IgA, IgG |
|<small>IgM, IgA, IgG</small> |
||
|<small>3</small> |
|||
|3 |
|||
<small>4 m</small> |
|||
4 m |
|||
|<small>59</small> |
|||
|59 |
|||
|Títulos altos a los 3 d post inicio de síntomas |
|<small>Títulos altos a los 3 d post inicio de síntomas</small> |
||
<br /> |
<small><br /></small> |
||
| |
| |
||
|Amanat et al. Medxriv (Mount Sinai) https://doi.org/10.1101/2020.03.17.20037713 |
|<small>Amanat et al. Medxriv (Mount Sinai) https://doi.org/10.1101/2020.03.17.20037713</small> |
||
Muestra tomadas días 2,4,6 y 20 |
<small>Muestra tomadas días 2,4,6 y 20</small> |
||
Controles de banco con otras inf virales |
<small>Controles de banco con otras inf virales |
||
Respuesta fuerte a IgM, IgA e IgG3 |
Respuesta fuerte a IgM, IgA e IgG3</small> |
||
Destinado a estudios de seroprevalencia y detección de personal de salud inmunes |
<small>Destinado a estudios de seroprevalencia y detección de personal de salud inmunes</small> |
||
|} |
|} |
||
"c+" = control positivo, m = muestras, p = pacientes, "- > +" = Negativo luego positio, "p+" = paciente confirmado, "p-" = paciente descartado. |
"c+" = control positivo, m = muestras, p = pacientes, "- > +" = Negativo luego positio, "p+" = paciente confirmado, "p-" = paciente descartado. |
Revisión actual - 14:44 25 mar 2020
Si no puedes ver bien la tabla, acá la versión en PDF: Tabla en PDF
Resumen realizado por Dra. Katia Abarca. Infectóloga Pediatra - P. Universidad Católica de Chile.
Tabla Resumen
Test/Manufacturador | Ac medido | n pos | n
controles |
S | E | Referencias
Comentarios usos |
---|---|---|---|---|---|---|
STANDARD Q COVID-19
Duo Inmunocromatográfico
|
IgM/IgG | 33 | 30 | IgM 63,3%
IgG 81.8% IgM + IgG 81.8% IgM dp D8: 77.8% IgM dp D10: 81.8% IgG dp D8: 92.6% IgG dp D10: 95.8% |
100%
96.6% 96.6% 100% 100% 96.6% 96.6% |
http://sdbiosensor.com/xe/product/7662.
|
Lateral flow immunoassay (tipo test pack) | IgM + IgG |
397 | 128 | 88.7%
352 + |
90.63%
12 c+ |
Zhengtu Li et al. J Med Virol 2020 27Feb. doi: https://doi.org/10.1002/jmv.25727.
Rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. Muestras consistencia suero y gota de sangre |
ELISA Gold inmunocromatográfico colloidal (GICA)
Diagnostics Inc |
IgM e IgG | 63 ELISA
91 GICA |
35 | ELISA:
IgM 44.4% IgG 82.5% IgM IgG 87.3% (55 +) GICA: IgM 57.1% IgG 81.3% IgM IgG 82.4% (75 +) |
100% 100% 100%
100% 100% 100% |
Xiang et al. https://doi.org/10.1101/2020.02.27.20028787.
|
Quimoluminiscencia (CHL)
ELISA (doble sandwich) GICA (point of care) |
Ac totales, IgM | CHL:
Ac totales 86.9% IgM 74.3% ELISA: Ac totales 94.8% IgM 86.9% GICA: Ac totales 96.2% IgM 87.9%
|
95.2-100% | Xia et al. doi:https://doi.org/10.20944/preprints202003.0184.v1.
(No peer reviewed) Testear casos oligo o asintomáticos para indicar cuarentena
| ||
Inmunoensayo
quimoluminiscente |
IgM IgG | 3 | 225 | Se + 7-12 d después
del inicio de síntomas |
98-100% | Zhang et al. MedXriv pre print https://doi.org/10.1101/2020.03.04.20030916.
|
Inmunocromatográfico | IgM IgG | 139 m
105 p 76 p+ 8 - > +
|
37 m
39 p |
IgM
1-7 d 11.1% 8-14 d 78.6% >15 d 74.2% IgG 1-7 d 3.6% 8-14 d 57.1% >15 d 96.8% IgM IgG 8-14: 92.9% |
Pan et al. MedRxiv preprinthttps://doi.org/10.1101/2020.03.13.20035428.
| |
CLIA (quemoluminiscente)
GICA (Gold inmunocromatográfico coloidal) ELISA
|
IgM IgG | 37 m
22 p+ |
NA | IgM (al menos uno +)
1-7 d 6/10 8-14 d 7/13 >15 d 11/14 IgG (al menos uno +) 1-7 d 5/10 8-14 d 10/13 >15 d 14/14
|
Hui-Xia Gao et al. Chinese Medical Journal 2020. DOI: https://doi.org/10.1097/CM9.0000000000000820
ELISA mejor para IgG | |
ELISA contra N | IgA, IgG e IgM | 208 m
82 p+ 58 p- |
285 | IgM
1-7 d 35/41 85.4% Mediana + IgM e IgA 7 d (3-6) IgG 14 d (10-18) IgM casos confirmados 75.6% IgM casos probables 93.2% Dp D5 + IgM>S que PCR S PCR: 1-3 d >90% D6 <80% (57.1-95.7) D14 <50% (23.7-59.5) |
Guo et al. Respuesta inmune precoz. https://doi.org/10.1093/cid/ciaa310/5810754
S PCR (1 test): 51.9% S IgM + PCR: 98.6% Reactividad cruzada con SARS-Covid, no con otros coronavirus Proponen uso en: Casos sospechosos PCR - Estudios de seroprevalencia y conocer tasa de asintomáticos Conocer estado inmune de personal de salud Detectar casos subclínicos | |
ELISA Contra S | IgM, IgA, IgG | 3
4 m |
59 | Títulos altos a los 3 d post inicio de síntomas
|
Amanat et al. Medxriv (Mount Sinai) https://doi.org/10.1101/2020.03.17.20037713
Muestra tomadas días 2,4,6 y 20 Controles de banco con otras inf virales Respuesta fuerte a IgM, IgA e IgG3 Destinado a estudios de seroprevalencia y detección de personal de salud inmunes |
"c+" = control positivo, m = muestras, p = pacientes, "- > +" = Negativo luego positio, "p+" = paciente confirmado, "p-" = paciente descartado.